The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes

OBJECTIVE: Despite advances in exogenous insulin therapy, many patients with type 1 diabetes do not achieve acceptable glycemic control and remain at risk for ketosis and insulin-induced hypoglycemia. We conducted a randomized controlled trial to determine whether TTP399, a novel hepatoselective glu...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Klara R., Freeman, Jennifer L.R., Dunn, Imogene, Dvergsten, Chris, Kirkman, M. Sue, Buse, John B., Valcarce, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2021
Materias:
Emerging Therapies: Drugs and Regimens
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985421/
https://www.ncbi.nlm.nih.gov/pubmed/33622669
http://dx.doi.org/10.2337/dc20-2684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985421/
https://www.ncbi.nlm.nih.gov/pubmed/33622669
http://dx.doi.org/10.2337/dc20-2684

Ejemplares similares